NEW YORK, Dec. 20 – German pharmaceutical company Schering said Thursday it had agreed to make a 10 percent equity investment in MorphoSys of Martinsreid, Germany, and to work together with the biotechnology firm to develop antibody therapeutics and diagnostics. 

Under the terms of the three-year deal, the companies said they would work together exclusively to develop at least five therapeutic and several in-vivo diagnostics antibody projects.  

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.